Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study

医学 中止 内科学 临床终点 耐火材料(行星科学) 临床研究阶段 淋巴瘤 胃肠病学 肿瘤科 临床试验 天体生物学 物理
作者
Yuqin Song,Luis Malpica,Qingqing Cai,Weili Zhao,Keshu Zhou,Jianqiu Wu,Huilai Zhang,Neha Mehta‐Shah,Kaiyang Ding,Yao Liu,Zengjun Li,Liling Zhang,Meifang Zheng,Jie Jin,Haiyan Yang,Yue-Rong Shuang,Dok Hyun Yoon,Sujun Gao,Wenyu Li,Zhimin Zhai
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:25 (1): 117-125 被引量:19
标识
DOI:10.1016/s1470-2045(23)00589-2
摘要

Background Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, has shown encouraging anti-tumour activity in heavily pre-treated patients with relapsed or refractory peripheral T-cell lymphoma in a phase 1 study (JACKPOT8 Part A). Here, we report the full analysis of a phase 2 study, in which we assessed the anti-tumour activity of golidocitinib in a large multinational cohort of patients. Methods We did a single-arm, multinational, phase 2 trial (JACKPOT8 Part B) in 49 centres in Australia, China, South Korea, and the USA. Eligible patients were adults (aged ≥18 years) with relapsed or refractory peripheral T-cell lymphoma who had received at least one previous line of systemic therapy and an Eastern Cooperative Oncology Group performance status of 0–2. Patients were given oral golidocitinib 150 mg once daily until disease progression or other discontinuation criteria were met. The primary endpoint was the CT-based objective response rate, assessed by an independent review committee (IRC) per Lugano 2014 classification. The activity analysis set included all patients who received at least one dose and whose pathological diagnosis of peripheral T-cell lymphoma had been retrospectively confirmed by a central laboratory and who had at least one measurable lesion at baseline assessed by IRC. The safety analysis set included all patients who received at least one dose of study drug. This study is registered with ClinicalTrials.gov, NCT04105010, and is closed to accrual and follow-up is ongoing. Findings Between Feb 26, 2021, and Oct 12, 2022, we assessed 161 patients for eligibility, of whom 104 (65%) were enrolled and received at least one dose of study drug; the activity analysis set included 88 (85%) patients (median age 58 years [IQR 51–67], 57 [65%] of 88 were male, 31 [35%] were female, and 83 [94%] were Asian). As of data cutoff (Aug 31, 2023; median follow-up was 13·3 months [IQR 4·9–18·4]), per IRC assessment, the objective response rate was 44·3% (95% CI 33·7–55·3; 39 of 88 patients, p<0·0001), with 21 (24%) patients having a complete response and 18 (20%) having a partial response. In the safety analysis set, 61 (59%) of 104 patients had grade 3–4 drug-related treatment-emergent adverse events. The most common grade 3–4 drug-related treatment-emergent adverse events were neutrophil count decreased (30 [29%]), white blood cell count decreased (27 [26%]), lymphocyte count decreased (22 [21%]), and platelet count decreased (21 [20%]), which were clinically manageable and reversible. 25 (24%) patients had treatment-related serious adverse events. Deaths due to treatment-emergent adverse events occurred in three (3%) patients: two (2%) due to pneumonia (one case with fungal infection [related to golidocitinib] and another one with COVID-19 infection) and one (1%) due to confusional state. Interpretation In this phase 2 study, golidocitinib showed a favourable benefit–risk profile in treating relapsed or refractory peripheral T-cell lymphoma. The results of this study warrant further randomised clinical studies to confirm activity and assess efficacy in this population. Funding Dizal Pharmaceutical.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
2秒前
3秒前
fuguier发布了新的文献求助10
4秒前
6秒前
zsk1122完成签到,获得积分10
8秒前
荔枝发布了新的文献求助10
8秒前
lyy完成签到 ,获得积分10
9秒前
12秒前
myuniv完成签到,获得积分10
12秒前
专注鸵鸟完成签到,获得积分10
12秒前
专注之双完成签到,获得积分10
13秒前
Zircon完成签到 ,获得积分10
14秒前
Much完成签到 ,获得积分10
15秒前
15秒前
充电宝应助颠覆乾坤采纳,获得10
16秒前
17秒前
无花果应助pz采纳,获得10
17秒前
zheng完成签到 ,获得积分10
19秒前
量子星尘发布了新的文献求助10
20秒前
星辰大海应助荔枝采纳,获得10
20秒前
LJL发布了新的文献求助10
21秒前
meng发布了新的文献求助10
21秒前
无私的颤完成签到,获得积分10
21秒前
lucky完成签到 ,获得积分10
22秒前
Zel博博完成签到,获得积分10
22秒前
谷粱诗云完成签到,获得积分10
22秒前
yar应助myuniv采纳,获得10
22秒前
xc完成签到 ,获得积分10
23秒前
23秒前
干净的天与完成签到,获得积分10
23秒前
哈基米德应助毅诚菌采纳,获得10
25秒前
铁甲小杨完成签到,获得积分0
25秒前
26秒前
卡机了完成签到,获得积分10
27秒前
平淡绿柏完成签到,获得积分10
29秒前
架子猫发布了新的文献求助10
29秒前
29秒前
颠覆乾坤发布了新的文献求助10
30秒前
乔乔完成签到,获得积分10
31秒前
学术小白完成签到,获得积分10
31秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038235
求助须知:如何正确求助?哪些是违规求助? 3575992
关于积分的说明 11374009
捐赠科研通 3305760
什么是DOI,文献DOI怎么找? 1819276
邀请新用户注册赠送积分活动 892662
科研通“疑难数据库(出版商)”最低求助积分说明 815022